Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393794 · ClinicalTrials.gov registry record · Phase 1
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
A Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Priyanka Sharma.
- Active
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 7
- Study locations
NCT02393794 is a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer that is active but no longer recruiting, run by Priyanka Sharma. The registered enrollment target is 51 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT02393794, a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Priyanka Sharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 7
- Study locations
Study Summary
Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Nivolumab
- DRUG Romidepsin
Study Locations (7)
Kansas
- University of Kansas Cancer Center - Clinical Research Center - Fairway
- University of Kansas Cancer Center - West - Kansas City
- University of Kansas Cancer Center - Overland Park - Overland Park
- University of Kansas Cancer Center - Westwood - Westwood
Missouri
- University of Kansas Cancer Center - South - Kansas City
- University of Kansas Cancer Center - North - Kansas City
- University of Kansas Cancer Center - Lee's Summit - Lee's Summit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-07-17 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393794
The ClinicalTrials.gov registry entry for NCT02393794 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Priyanka Sharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02393794 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT02393794 about?
NCT02393794 is a clinical study titled "Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)". Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer
What is the current status of trial NCT02393794?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2015-07-17. Estimated completion is 2026-07.
What conditions does trial NCT02393794 study?
This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT02393794?
The interventions under investigation include: Cisplatin (DRUG), Nivolumab (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT02393794?
This trial is sponsored by Priyanka Sharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02393794 being conducted?
This trial has 7 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.